Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy

a technology of tricyclic lactams and normal cells, applied in the field of tricyclic lactam compounds and compositions, can solve the problems of non-specific chemotherapeutic compounds, rapid cell division, and variety of side effects in patients undergoing chemotherapy, and achieve the effect of reducing the effect of chemotherapeutic agent toxicity

Inactive Publication Date: 2015-10-22
G1 THERAPEUTICS INC
View PDF0 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0029]Methods and tricyclic lactam compounds are provided to minimize the effect of chemotherapeutic agent toxicity on CDK4/6 replication dependent healthy cells, such as hematopoietic stem cells and hematopoietic ...

Problems solved by technology

Chemotherapeutic compounds tend to be non-specific and, particularly at high doses, toxic to normal, rapidly dividing cells.
This often leads to a variety of side effects in patients undergoing chemotherapy.
Myelosuppression continues to represent the major dose-limiting toxicity of cancer chemotherapy, resulting in considerable morbidity along with the potential need to require a reduction in chemotherapy dose intensity, which may compromise disease control and survival.
In addition to bone marrow suppression, chemotherapeutic agents can adversely affect other healthy cells such as renal epithelial cells, resulting potentially in the development of acute kidney injury due to the death of the tubular epithelia.
Acute kidney injury can lead to chronic kidney disease,...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
  • Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
  • Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Compound 2 (Scheme 1)

[0367]Compound 2 is synthesized according to the method of A. Haidle et al., See, WO 2009 / 152027 entitled 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one derivatives for MARK inhibition.

example 2

Synthesis of Compound 3 (Scheme 1)

[0368]Step 1: A round-bottomed flask inerted with a nitrogen atmosphere is charged with Compound 2, ethanol, and lithium borohydride at ambient temperature. The reaction is stirred at ambient temperature and monitored by thin layer chromatography (TLC) or HPLC. Once Compound 2 can no longer be detected, the reaction is quenched with an aqueous acid such as aqueous hydrochloric acid, diluted with ethyl acetate and the layers separated. The organic layer is dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The product, a primary alcohol, is purified by silica gel column chromatography eluting with a hexane-ethyl acetate gradient and used directly in the next step.

[0369]Step 2: A round-bottomed flask inerted with a nitrogen atmosphere is charged with the primary alcohol prepared in step 1, DMF and phosphorus tribromide. The reaction is stirred at ambient temperature and monitored by thin layer chromatography (TLC) or HPLC. Onc...

example 3

Synthesis of Compound 5 (Scheme 1)

[0370]A round-bottomed flask inerted with a nitrogen atmosphere is charged with tetrahydrofuran and the lactam 4, described below. The reaction is cooled to −78° C. and lithium diisopropylamide solution (2M in THF / heptane / ethyl benzene) is added dropwise. To the resulting enolate is added Compound 3, dropwise, and the reaction is allowed to warm to room temperature overnight. The reaction is diluted with saturated brine and the layers are separated. The organic layer is dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The product is purified by silica gel column chromatography eluting with a dichloromethane-methanol gradient.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

This invention is in the area of tricyclic lactam compounds, compositions and methods of protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, protection of healthy cells is disclosed using compounds that act as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of provisional U.S. Application No. 61 / 980,883, filed Apr. 17, 2014, provisional U.S. Application No. 61 / 980,895, filed Apr. 17, 2014, provisional U.S. Application No. 61 / 980,918, filed Apr. 17, 2014, and provisional U.S. Application No. 61 / 980,939, filed Apr. 17, 2014, which are hereby incorporated by reference for all purposes.GOVERNMENT INTEREST[0002]The U.S. Government has rights in this invention by virtue of support under Grant No. 5R44AI084284 awarded by the National Institute of Allergy and Infectious Diseases.FIELD OF THE INVENTION[0003]This invention is in the area of tricyclic lactam compounds, compositions, and methods of protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.BACKGROUND[0004]Chemotherapy refers to the use of cytotoxic (typically DNA damaging) drugs to treat a range of pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/5377A61K31/519A61K31/527
CPCA61K31/5377A61K31/527A61K31/519A61K45/06C07D471/20C07D487/14C07D487/20
Inventor STRUM, JAY COPELANDBISI, JOHN EMERSONROBERTS, PATRICK JOSEPHGASTON, RICKY D.GADWOOD, ROBERT C.
Owner G1 THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap